Korea Tries To Buffer Heavy Price Cuts With R&D Incentives, But Local And Global Pharma Up In Arms
This article was originally published in PharmAsia News
TOKYO - South Korea's Ministry of Health and Welfare announced this week dual measures to drastically cut drug prices, while also committing to support Korea's innovation-focused companies through tax credits and preferential pricing
You may also be interested in...
Faced with opposition from pharma companies jittery over the potential for more price cuts, the Ministry of Health and Welfare is considering a market-based actual transaction pricing system, which awards institutions for buying cheaper drugs.
Hanmi is the first to clear regulatory hurdles to sell the country’s best-selling hepatitis B therapy after patent expiration in 2015, though the distinction doesn’t carry the same benefits as it once did.
The Korea Drug Development Fund and the Health Ministry are pursuing two separate projects, but targeting the same goal of helping R&D-focused companies.